Supernus Pharmaceuticals (SUPN) News Today → My next big prediction isn’t a prediction (From Porter & Company) (Ad) Free SUPN Stock Alerts $34.19 +1.21 (+3.67%) (As of 03/18/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSupernus Pharmaceuticals executive trades company stockinvesting.com - March 16 at 8:45 PMSUPN Apr 2024 29.000 callfinance.yahoo.com - March 16 at 10:13 AMPadmanabh P. Bhatt Sells 3,884 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stockinsidertrades.com - March 16 at 6:32 AMSupernus Pharmaceuticals executive sells over $2.1m in stockinvesting.com - March 15 at 7:01 PMSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Polar Capital Holdings Plcmarketbeat.com - March 11 at 1:50 PMSupernus to Participate in Two Upcoming Investor Conferencesglobenewswire.com - March 6 at 4:30 PMSupernus Pharmaceuticals: Moving Through An 'Inflection Year'seekingalpha.com - March 4 at 11:41 AMInvesco Ltd. Sells 64,791 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)marketbeat.com - March 3 at 5:22 AMSupernus Pharmaceuticals Full Year 2023 Earnings: Beats Expectationsfinance.yahoo.com - February 29 at 7:35 AMConnor Clark & Lunn Investment Management Ltd. Raises Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)marketbeat.com - February 29 at 6:48 AMSupernus to Participate in the TD Cowen 44th Annual Healthcare Conferenceglobenewswire.com - February 28 at 4:30 PMPiper Sandler Reaffirms Their Buy Rating on Supernus Pharmaceuticals (SUPN)markets.businessinsider.com - February 28 at 3:33 PMSupernus Pharmaceuticals (NASDAQ:SUPN) PT Lowered to $41.00marketbeat.com - February 28 at 11:14 AMSupernus Pharmaceuticals (NASDAQ:SUPN) Releases Earnings Results, Misses Estimates By $0.39 EPSmarketbeat.com - February 28 at 10:42 AMQ4 2023 Supernus Pharmaceuticals Inc Earnings Callfinance.yahoo.com - February 28 at 10:33 AMSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 28 at 10:33 AMStrong Buy for Supernus Pharmaceuticals on Qelbree’s Robust Sales Growth and Positive Market Outlookmarkets.businessinsider.com - February 28 at 5:32 AMRecap: Supernus Pharmaceuticals Q4 Earningsbenzinga.com - February 27 at 5:32 PMSupernus Pharmaceuticals Inc (SUPN) Reports Robust Growth in Key Products for Full Year 2023finance.yahoo.com - February 27 at 5:32 PMSupernus Announces Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - February 27 at 4:05 PMEpoch Investment Partners Inc. Sells 88,386 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)marketbeat.com - February 26 at 8:30 AMRetirement Planning Co of New England Inc. Has $1.42 Million Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)marketbeat.com - February 21 at 3:33 PMState Board of Administration of Florida Retirement System Sells 31,877 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)marketbeat.com - February 19 at 5:23 AMSUPN Mar 2024 39.000 callfinance.yahoo.com - February 17 at 8:25 PMSUPN Mar 2024 28.000 putfinance.yahoo.com - February 17 at 3:24 PMSUPN Mar 2024 42.000 callfinance.yahoo.com - February 17 at 10:23 AMShort Interest in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Drops By 16.9%marketbeat.com - February 16 at 11:37 PMLoomis Sayles & Co. L P Boosts Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)marketbeat.com - February 15 at 10:31 AMSupernus Pharmaceuticals Incmoney.usnews.com - February 14 at 8:18 PMSupernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024finance.yahoo.com - February 13 at 6:40 PMBurney Co. Sells 114,648 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)marketbeat.com - February 8 at 9:52 AMSupernus Pharmaceuticals Wins Patent Infringement Lawsuitmsn.com - February 6 at 10:34 AMSupernus Pharmaceuticals, Inc.: Supernus Wins Infringement and Validity Case on Trokendi XR against Torrentfinanznachrichten.de - February 5 at 1:28 PMSupernus Pharma Wins Infringement, Validity Case On Trokendi XR Against Torrentmarkets.businessinsider.com - February 5 at 1:28 PMSupernus Pharmaceuticals, Inc. (SUPN)finance.yahoo.com - February 4 at 5:38 PMVictory Capital Management Inc. Boosts Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)marketbeat.com - February 3 at 4:42 AMIllinois Municipal Retirement Fund Acquires New Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)marketbeat.com - February 2 at 5:58 AMCongress Asset Management Co. MA Grows Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)marketbeat.com - January 18 at 8:15 AMSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?finance.yahoo.com - January 14 at 8:09 AMSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Tami Tillotson Martin Sells 8,000 Sharesmarketbeat.com - January 12 at 6:41 PM3 Pharma Stocks to Buy Before Year-Endstocknews.com - December 26 at 2:26 PM3 Rising Pharma Stocks to Consider Buying Nowstocknews.com - December 7 at 1:12 PMSupernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 8.7% CAGR over the last three yearsfinance.yahoo.com - December 4 at 2:38 PMBoard Member at Supernus Pharmaceuticals Exercises Options Worth $203Kbenzinga.com - November 21 at 1:40 PMInsider Sell Alert: Director Frederick Hudson Sells 9,093 Shares of Supernus Pharmaceuticals ...finance.yahoo.com - November 18 at 8:01 AMSupernus Pharmaceuticals: Derisked CNS Drug Portfolio Offers Attractive Buying Opportunityseekingalpha.com - November 10 at 5:53 PMSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 10 at 12:51 PMPromising Progress and Potential of Qelbree Bolsters Buy Rating for Supernus Pharmaceuticalsmarkets.businessinsider.com - November 10 at 7:50 AMQ3 2023 Supernus Pharmaceuticals Inc Earnings Callfinance.yahoo.com - November 9 at 11:45 AMSupernus Pharmaceuticals (SUPN) Reports Q3 Loss, Tops Revenue Estimatesfinance.yahoo.com - November 8 at 10:45 PM Get Supernus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now SUPN Media Mentions By Week SUPN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SUPN News Sentiment▼0.480.62▲Average Medical News Sentiment SUPN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SUPN Articles This Week▼52▲SUPN Articles Average Week Get Supernus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PCRX News CORT News ARQT News ORIC News INVA News OCUL News PHAT News KPTI News BTAI News PRGO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SUPN) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Companytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.